<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1403</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2023-22-3-28-35</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">mRNA of the <italic>OY-TES-1</italic> gene in peripheral blood and tumors in colorectal cancer</article-title><trans-title-group xml:lang="ru"><trans-title>мРНК гена <italic>OY-TES-1</italic> в периферической крови и опухоли при колоректальном раке</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8367-6118</contrib-id><name-alternatives><name xml:lang="en"><surname>Hilal</surname><given-names>N. R.</given-names></name><name xml:lang="ru"><surname>Хилал</surname><given-names>Н. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>23 Gagarin ave., Nizhny Novgorod 603022</p><p>10 / 1 Minin and Pozharsky sq., Nizhny Novgorod 603000</p></bio><bio xml:lang="ru"><p>603022 Нижний Новгород, пр-кт Гагарина, 23</p><p>603000 Нижний Новгород, площадь Минина и Пожарского, 10 / 1</p><p> </p></bio><email>nadia.hilal@hotmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7049-6935</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>23 Gagarin ave., Nizhny Novgorod 603022</p><p>71 Malaya Yamskaya St., Nizhny Novgorod 603022</p><p> </p></bio><bio xml:lang="ru"><p>603022 Нижний Новгород, пр-кт Гагарина, 23</p><p>603022 Нижний Новгород, ул. Малая Ямская, 71</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7150-7851</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakimov</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Якимов</surname><given-names>В. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>23 Gagarin ave., Nizhny Novgorod 603022</p></bio><bio xml:lang="ru"><p>603022 Нижний Новгород, пр-кт Гагарина, 23</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1614-9347</contrib-id><name-alternatives><name xml:lang="en"><surname>Pegov</surname><given-names>R. G.</given-names></name><name xml:lang="ru"><surname>Пегов</surname><given-names>Р. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>11 / 1 Delovaya St., Nizhny Novgorod 603093</p></bio><bio xml:lang="ru"><p>603093 Нижний Новгород, ул. Деловая, 11 / 1</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2449-7213</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>23 Gagarin ave., Nizhny Novgorod 603022</p><p>71 Malaya Yamskaya St., Nizhny Novgorod 603022</p><p> </p></bio><bio xml:lang="ru"><p>603022 Нижний Новгород, пр-кт Гагарина, 23</p><p>603022 Нижний Новгород, ул. Малая Ямская, 71</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research N. I. Lobachevsky Nizhegorodsky State University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Национальный исследовательский Нижегородский государственный университет им. Н. И. Лобачевского»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Privolzhsky Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Academician I. N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">ФГБУН «Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И. Н. Блохиной» Росспотребнадзора</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Nizhny Novgorod Regional Clinical Oncology Center</institution></aff><aff><institution xml:lang="ru">Нижегородский областной клинический онкологический диспансер</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-10-18" publication-format="electronic"><day>18</day><month>10</month><year>2023</year></pub-date><volume>22</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>28</fpage><lpage>35</lpage><history><date date-type="received" iso-8601-date="2023-10-17"><day>17</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-17"><day>17</day><month>10</month><year>2023</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1403">https://bioterapevt.abvpress.ru/jour/article/view/1403</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>One of the testicular cancer genes is the <italic>OY-TES-1</italic> gene, which encodes a proacrosin-binding protein. This gene is known to be expressed in tumor cells.</p><p><bold>Aim.</bold> To determinate the detection frequency of <italic>OY-TES-</italic>1 matrix ribonucleic acid (mRNA) in the peripheral blood and tumor of patients with colorectal cancer (CRC) in comparison with the clinical features of the course of a disease in order to assess the potential monitoring significance of this indicator.</p><p><bold>Materials and methods. </bold>A method for determining the level of <italic>OY-TES-1</italic> mRNA based on reverse transcription polymerase chain reaction (RT-PCR). The detection frequency of mRNA <italic>OY-TES-1</italic> gene in blood and tumor samples of 66 patients with CRC, as well as the blood of healthy volunteers, was evaluated.</p><p><bold>Results.</bold> In the peripheral blood of healthy volunteers, no <italic>OY-TES-1</italic> mRNA was detected. In the blood of CRC patients, <italic>OY-TES-1 </italic>mRNA was detected in 13.6 % of cases. In tumors, it was found in 60,6 % of cases. <italic>OY-TES</italic>-1 mRNA in the blood and in tumor of patients with CRC was detected statistically significantly more often at stages III and IV than at stages I and II (11,0 and 4,5 times, respectively), and also many times more often in tumors with a low degree of differentiation than with highly differentiated tumors. In patients with CRC, the <italic>OY-TES-1</italic> mRNA in tumors with metastases in organs and lymph nodes was detected many times more often than in tumors without any metastases (by 16,4 and 17,4 times respectively).</p><p><bold>Conclusion. </bold>The data obtained indicate the absence of mRNA OY-TES-1gene in the blood of healthy individuals, the appearance of mRNA <italic>OY-TES-1</italic> gene in the blood of CRC patients, and the possibility of using the detection of mRNA <italic>OY-TES-1 </italic>gene in the blood as an additional informative monitoring marker for colorectal cancer.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Одним из раково-тестикулярных генов является ген <italic>OY-TES-1</italic>, кодирующий проакрозинсвязывающий белок. Известно об экспрессии этого гена в опухолевых клетках.</p><p><bold>Цель исследования</bold> – определение частоты обнаружения матричной рибонуклеиновой кислоты (мРНК) <italic>OY-TES-1</italic>  в периферической крови и опухолевых очагах больных колоректальным раком (КРР) в сопоставлении с клиническими особенностями течения заболевания для оценки потенциальной мониторинговой значимости данного показателя.</p><p><bold>Материалы и методы.</bold> Использован метод определения мРНК <italic>OY-TES-1</italic>  на основе полимеразной цепной реакции с обратной транскрипцией, и проведена оценка частоты встречаемости мРНК OY-TES-1  в периферической крови и опухолевых очагах 66 больных КРР, а также в крови здоровых волонтеров с помощью построения таблиц сопряженности, использования критерия χ2 и точного критерия фишера.</p><p><bold>Результаты. </bold>В периферической крови здоровых волонтеров мРНК <italic>OY-TES-</italic>1  не обнаруживалась. В крови больных КРР мРНК <italic>OY-TES-1</italic>  выявлена в 13,6 % случаев. В опухолях она обнаруживалась в 60,6 % случаев. В крови и опухолевых очагах больных КРР мРНК <italic>OY-TES-</italic>1  выявлялась статистически значимо чаще на III и IV стадиях, чем на I и II стадиях (в 11,0 и 4,5 раза соответственно), а также многократно чаще при опухолях с низкой степенью дифференцировки, чем при высокодифференцированных опухолях. У больных КРР мРНК OY-TES-1  в опухолях при метастазах в органах и лимфатических узлах обнаруживалась многократно чаще, чем при их отсутствии (в 16,4 и 17,4 раза соответственно).</p><p><bold>Заключение</bold>. Полученные данные свидетельствуют об отсутствии мРНК гена <italic>OY-TES-1</italic>  в крови здоровых лиц и появлении мРНК гена <italic>OY-TES-1</italic>  в крови больных КРР. Показана возможность использования теста на наличие в крови мРНК гена <italic>OY-TES-1</italic>  в качестве дополнительного информативного мониторингового показателя при КРР.</p></trans-abstract><kwd-group xml:lang="en"><kwd><italic>OY-TES-1</italic></kwd><kwd>cancer-testis genes</kwd><kwd>expression level</kwd><kwd>colorectal cancer</kwd><kwd>reverse transcription polymerase chain reaction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd><italic>OY-TES-1</italic></kwd><kwd>раково-тестикулярные гены</kwd><kwd>колоректальный рак</kwd><kwd>полимеразная цепная реакция с обратной транскрипцией</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Liu W-S. Mammalian Sex Chromosome Structure, Gene Content, and Function in Male Fertility. Annu Rev Anim Biosci 2019;15(7):103–24. DOI: 10.1146/annurev-animal-020518-115332</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Golyshko P.V., Novikov D.V., Ananiev S.V. et al. Cancertesticular genes in the blood and tumors of patients with colorectal cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(1):19–24. (In Russ.). DOI: 10.17650/1726-9784-2015-14-1-19-24.</mixed-citation><mixed-citation xml:lang="ru">Голышко П.В., Новиков Д.В., Ананьев С.В. и др. Раково-тестикулярные гены в крови и опухоли больных колоректальным раком. Российский биотерапевтический журнал 2015;14(1):19–24. DOI: 10.17650/1726-9784-2015-14-1-19-24</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Gu L., Sang M., Yin D. et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer. Thorac Cancer 2018;9(4):431–8. DOI: 10.1111/1759-7714.12571</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kanemori Y., Ryu J.H., Sudo M. et al. Two functional forms of ACRBP/sp32 are produced by pre-mRNA alternative splicing in the mouse. Biol Reprod 2013;88:105. DOI: 10.1095/biolreprod.112.107425</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cen Y.H., Guo W.W., Luo B. et al. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol Int 2012;36:917–22. DOI: 10.1042/CBI20120037</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bin L., Xiang Y., Jing L. et al. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Current Medical Science 2020;40:719–28. DOI: 10.1007/s11596-020-2241-x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lin L., Nong W., Luo B. et al. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: its association with prognosis. Immunity, Inflammation and Disease 2021;9(4):1759–70. DOI: 10.1002/iid3.534</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kazemi-oula G., Ghafouri-Fard S., Mobasheri M.B. et al. Upregulation of RHOXF2 and ODF4 Expression in Breast Cancer Tissues. Cell Journal 2015;17:471–7. DOI:10.22074/CELLJ.2015.8</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bin L., Xiang Y., Rong F. et al. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol 2013;6(12):2835–45.</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Hilal N.R., Novikov D.V., Novikov V.V., Karaulov A.V. Cancertesticular genes in colon cancer. Terapevticheskiy arkhiv = Therapeutic Archive 2017;113–7. (In Russ.). DOI: 10.17116/terarkh2017895113-117</mixed-citation><mixed-citation xml:lang="ru">Хилал Н.Р., Новиков Д.В., Новиков В.В., Караулов А.В. Раково-тестикулярные гены при раке толстой кишки. Терапевтический архив 2017;113–7. DOI: 10.17116/terarkh2017895113-117</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kalugin A.V., Novikov D.V., Mamaeva M.E. et al. Cancer-testis genes mRNA presence in tumor lesion and peripheral blood of endometrial cancer patients. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2022;21(2):33–9. (In Russ.). DOI: 10.17650/1726-9784-2022-21-2-33-39</mixed-citation><mixed-citation xml:lang="ru">Калугин А.В., Новиков Д.В., Мамаева М.Е. и др. Присутствие мРНК раково-тестикулярных генов в опухоли и периферической крови больных раком эндометрия. Российский биотерапевтический журнал 2022;21(2):33–9. DOI: 10.17650/1726-9784-2022-21-2-33-39</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Maus M.K., Hanna D.L., Stephens C.L. et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 2015;15(4):354–62. DOI: 10.1038/tpj.2014.73</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Birkenkamp-Demtroder K., Olesen S.H., Sorensen F.B. et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54(3):374–84. DOI: 10.1136/gut.2003.036848</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Missiaglia E., Jacobs B., D’Ario G. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25(10):1995–2001. DOI: 10.1093/annonc/mdu275</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Xu S.Z., Ding Z.J., Zhang S.F. et al. Propensity score matching-based analysis of short-term outcomes of Laparoscopicassisted Natural Orifice Specimen Extraction for left colorectal cancer radical resection. Zhonghua Yi Xue Za Zhi 2016;96(20):1578–81. DOI: 10.3760/cma.j.issn.0376-2491. 2016.20.007</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dejea C.M., Wick E.C., Hechenbleikner E.M. et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014;111(51):18321–6. DOI: 10.1073/pnas.1406199111</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Almutairi M.H., Alrubie T.M., Almutairi B.O. et al. The Expression Patterns of Human Cancer-Testis Genes Are Induced through Epigenetic Drugs in Colon Cancer Cells. Pharmaceutical 2022;15(11):1319. DOI: 10.3390/ph15111319</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Thomas J., Starmans M.H.W., Yao-Tseng C. et al. The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS One 2013;8(7):e67876. DOI: 10.1371/journal.pone.0067876</mixed-citation></ref></ref-list></back></article>
